跳至主要内容
临床试验/NL-OMON56987
NL-OMON56987尚未招募不适用

Systemic Albumin Leakage as proxy for Vascular inflAmmaTion and cardiovascular disease in diabEtes patients; the SALVATE study - The SALVATE study

niversitair Medisch Centrum Groningen0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Men and women, age >= 18 years.
  • Written informed consent.
  • eGFR above 60 ml/min/1,73m2.
  • Using renin-angiotensin system (RAS) inhibitors.
  • Fulfils ADA criteria for diabetes.
  • o Fasting plasma glucose >= 7.0 mmol/l.
  • o Random plasma glucose >= 11.1 mmol/l.
  • o HbA1C >= 6,5%.

排除标准

  • Patients who are mentally incompetent and cannot sign a Patient Informed
  • Consent or are unwilling to sign a Patient Informed Consent.
  • Women who are currently pregnant, planning to become pregnant, breastfeeding
  • women, or women with childbearing potential not using appropriate contraceptive
  • measures. This will be discussed during the intake conversation and women who
  • answer yes on any of the previous questions will be excluded.
  • Other causes for macroalbuminuria than nephropathy.
  • Systemic auto-immune disease or vasculitis.
  • Inflammation of unknown origin or sepsis.
  • Patients who use immunosuppressives or anti-inflammatory drugs that could
  • interfere with the study results.
  • Recent (< 3 months) acute disease such as cardiovascular event or infection
  • for which admission to hospital was necessary.
  • Recent (< 3 months) surgical procedure, excluding procures under local
  • anaesthetics.
  • Active malignancy, excluding skin malignancies: basal cell carcinoma and
  • squamous cell carcinoma,
  • Patients who have claustrophobia.

研究者

相似试验